Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers.

Toriola AT, Cheng TY, Neuhouser ML, Wener MH, Zheng Y, Brown E, Miller JW, Song X, Beresford SA, Gunter MJ, Caudill MA, Ulrich CM.

Int J Cancer. 2013 Jun 1;132(11):2648-58. doi: 10.1002/ijc.27942. Epub 2012 Dec 5.

2.

Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Aleksandrova K, Jenab M, Bueno-de-Mesquita HB, Fedirko V, Kaaks R, Lukanova A, van Duijnhoven FJ, Jansen E, Rinaldi S, Romieu I, Ferrari P, Murphy N, Gunter MJ, Riboli E, Westhpal S, Overvad K, Tjønneland A, Halkjær J, Boutron-Ruault MC, Dossus L, Racine A, Trichopoulou A, Bamia C, Orfanos P, Agnoli C, Palli D, Panico S, Tumino R, Vineis P, Peeters PH, Duell EJ, Molina-Montes E, Quirós JR, Dorronsoro M, Chirlaque MD, Barricarte A, Ljuslinder I, Palmqvist R, Travis RC, Khaw KT, Wareham N, Pischon T, Boeing H.

Eur J Epidemiol. 2014 Apr;29(4):261-75. doi: 10.1007/s10654-014-9901-8. Epub 2014 May 4.

PMID:
24791703
3.

Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.

Shiels MS, Katki HA, Hildesheim A, Pfeiffer RM, Engels EA, Williams M, Kemp TJ, Caporaso NE, Pinto LA, Chaturvedi AK.

J Natl Cancer Inst. 2015 Jul 28;107(10). pii: djv199. doi: 10.1093/jnci/djv199. Print 2015 Oct.

PMID:
26220734
4.

Circulating inflammation markers and prospective risk for lung cancer.

Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, Katki HA, Koshiol J, Shelton G, Caporaso NE, Pinto LA, Chaturvedi AK.

J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80. doi: 10.1093/jnci/djt309. Epub 2013 Nov 18.

5.

Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma.

Meng YQ, Cao X, Wen ZS, Liu QW, Tan ZH, Duan H, Ma GW, Lin P.

Dis Esophagus. 2014 Sep-Oct;27(7):670-7. doi: 10.1111/dote.12128. Epub 2013 Aug 30.

PMID:
24033446
6.

Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.

Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM.

J Clin Oncol. 2009 Jul 20;27(21):3437-44. doi: 10.1200/JCO.2008.18.9068. Epub 2009 May 26.

7.

Evaluation of the diagnostic accuracy of plasma markers for early diagnosis in patients suspected for acute appendicitis.

Schellekens DH, Hulsewé KW, van Acker BA, van Bijnen AA, de Jaegere TM, Sastrowijoto SH, Buurman WA, Derikx JP.

Acad Emerg Med. 2013 Jul;20(7):703-10. doi: 10.1111/acem.12160.

8.

C-reactive protein levels are not associated with increased risk for colorectal cancer in women.

Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM.

Ann Intern Med. 2005 Mar 15;142(6):425-32.

PMID:
15767620
9.

Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men's Health Study.

Wu J, Cai Q, Li H, Cai H, Gao J, Yang G, Zheng W, Xiang YB, Shu XO.

Carcinogenesis. 2013 Dec;34(12):2799-803. doi: 10.1093/carcin/bgt288. Epub 2013 Aug 28.

10.

Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient.

Hogarth MB, Gallimore R, Savage P, Palmer AJ, Starr JM, Bulpitt CJ, Pepys MB.

Age Ageing. 1997 Mar;26(2):153-8.

PMID:
9177673
11.

Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases.

Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1342-8.e1. doi: 10.1016/j.cgh.2013.12.030. Epub 2014 Jan 7.

12.

C-reactive protein and risk of lung cancer.

Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, Chanock SJ, Goedert JJ, Engels EA.

J Clin Oncol. 2010 Jun 1;28(16):2719-26. doi: 10.1200/JCO.2009.27.0454. Epub 2010 Apr 26.

13.

C-reactive protein and the risk of incident colorectal cancer.

Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ.

JAMA. 2004 Feb 4;291(5):585-90.

PMID:
14762037
14.

Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.

Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM.

JAMA. 2002 Aug 28;288(8):980-7.

PMID:
12190368
15.

Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function.

Barassi A, Pezzilli R, Morselli-Labate AM, Lombardi F, Belletti S, Dogliotti G, Corsi MM, Merlini G, Melzi d'Eril GV.

Can J Cardiol. 2012 Sep-Oct;28(5):537-41. doi: 10.1016/j.cjca.2012.02.014. Epub 2012 May 1.

PMID:
22552174
16.

A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer.

Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, Fuchs CS, Ogino S, Giovannucci EL, Chan AT.

J Natl Cancer Inst. 2014 Apr;106(4):dju016. doi: 10.1093/jnci/dju016. Epub 2014 Feb 24.

17.

Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study.

Prizment AE, Anderson KE, Visvanathan K, Folsom AR.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):297-307. doi: 10.1158/1055-9965.EPI-10-1146. Epub 2011 Jan 7.

18.

The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer.

Zhang XY, Zhang G, Jiang Y, Liu D, Li MZ, Zhong Q, Zeng SQ, Liu WL, Zeng MS.

Chin J Cancer. 2015 Aug 10;34(8):335-49. doi: 10.1186/s40880-015-0039-1.

19.

Inflammatory markers and in-hospital mortality in acute ischaemic stroke.

Rallidis LS, Vikelis M, Panagiotakos DB, Rizos I, Zolindaki MG, Kaliva K, Kremastinos DT.

Atherosclerosis. 2006 Nov;189(1):193-7. Epub 2006 Jan 18.

PMID:
16388807
20.

Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk.

Davenport JR, Cai Q, Ness RM, Milne G, Zhao Z, Smalley WE, Zheng W, Shrubsole MJ.

Mol Carcinog. 2016 Aug;55(8):1251-61. doi: 10.1002/mc.22367. Epub 2015 Aug 31.

Supplemental Content

Support Center